Cargando…
Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352224/ https://www.ncbi.nlm.nih.gov/pubmed/32560243 http://dx.doi.org/10.3390/cancers12061594 |
_version_ | 1783557587846823936 |
---|---|
author | Lidenge, Salum J. Tso, For Yue Mortazavi, Yasaman Ngowi, John R. Shea, Danielle M. Mwaiselage, Julius Wood, Charles West, John T. |
author_facet | Lidenge, Salum J. Tso, For Yue Mortazavi, Yasaman Ngowi, John R. Shea, Danielle M. Mwaiselage, Julius Wood, Charles West, John T. |
author_sort | Lidenge, Salum J. |
collection | PubMed |
description | Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05 were considered significant. Subjects with patch and plaque KS lesions responded more favorably to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants with KS despite a clinical KS response. While patch and plaque KS lesions were more common among treatment responders, none of the analyzed viral and immunological parameters distinguished responders from non-responders at baseline or after treatment. |
format | Online Article Text |
id | pubmed-7352224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73522242020-07-21 Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients Lidenge, Salum J. Tso, For Yue Mortazavi, Yasaman Ngowi, John R. Shea, Danielle M. Mwaiselage, Julius Wood, Charles West, John T. Cancers (Basel) Article Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05 were considered significant. Subjects with patch and plaque KS lesions responded more favorably to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants with KS despite a clinical KS response. While patch and plaque KS lesions were more common among treatment responders, none of the analyzed viral and immunological parameters distinguished responders from non-responders at baseline or after treatment. MDPI 2020-06-16 /pmc/articles/PMC7352224/ /pubmed/32560243 http://dx.doi.org/10.3390/cancers12061594 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lidenge, Salum J. Tso, For Yue Mortazavi, Yasaman Ngowi, John R. Shea, Danielle M. Mwaiselage, Julius Wood, Charles West, John T. Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title | Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title_full | Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title_fullStr | Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title_full_unstemmed | Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title_short | Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients |
title_sort | viral and immunological analytes are poor predictors of the clinical treatment response in kaposi’s sarcoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352224/ https://www.ncbi.nlm.nih.gov/pubmed/32560243 http://dx.doi.org/10.3390/cancers12061594 |
work_keys_str_mv | AT lidengesalumj viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT tsoforyue viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT mortazaviyasaman viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT ngowijohnr viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT sheadaniellem viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT mwaiselagejulius viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT woodcharles viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients AT westjohnt viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients |